THE EFFECTS OF AROMATIC AND ALIPHATIC MALEIMIDE CROSSLINKERS ON ANTI-CD5 RICIN IMMUNOTOXINS

被引：15
作者：
MYERS, DE
UCKUN, FM
SWAIM, SE
VALLERA, DA
机构：
[1] UNIV MINNESOTA HOSP & CLIN,DEPT THERAPEUT RADIOL,BOX 367,HARVARD ST & E RIVER RD,MINNEAPOLIS,MN 55455
[2] UNIV MINNESOTA HOSP & CLIN,EXPTL CANC IMMUNOL SECT,MINNEAPOLIS,MN 55455
来源：
JOURNAL OF IMMUNOLOGICAL METHODS | 1989年 / 121卷 / 01期
关键词：
D O I：
10.1016/0022-1759(89)90428-6
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：129 / 142
页数：14
相关论文
共 50 条
  • [41] CELL-TYPE SPECIFIC CYTO-TOXICITY OF ANTI-CD4 AND ANTI-CD8 RICIN IMMUNOTOXINS AGAINST HUMAN ALLOREACTIVE T-CELL CLONES
    UCKUN, FM
    MYERS, DE
    LEDBETTER, JA
    WEE, SL
    VALLERA, DA
    BLOOD, 1989, 74 (07) : 2445 - 2454
  • [42] Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies
    Masayuki Wada
    Hongyu Zhang
    Liu Fang
    Jia Feng
    Charlotte Olivia Tse
    Wenli Zhang
    Qi Chen
    Sha Sha
    Yuanzhen Cao
    Kevin H. Chen
    Kevin G. Pinz
    Xi Chen
    Xing-Xing Fan
    Xun Jiang
    Yupo Ma
    Stem Cell Reviews and Reports, 2020, 16 : 369 - 384
  • [43] Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control
    Lin, Haolong
    Cheng, Jiali
    Zhu, Li
    Zeng, Yuhao
    Dai, Zhenyu
    Zhang, Yicheng
    Zhu, Xiaojian
    Mu, Wei
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [44] Apoptosis induction by hypercross-linking of the surface antigen CD5 with anti-CD5 monoclonal antibodies in B cell chronic lymphocytic leukemia
    Cioca, DP
    Kitano, K
    LEUKEMIA, 2002, 16 (03) : 335 - 343
  • [45] Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
    Chen, K. H.
    Wada, M.
    Pinz, K. G.
    Liu, H.
    Lin, K-W
    Jares, A.
    Firor, A. E.
    Shuai, X.
    Salman, H.
    Golightly, M.
    Lan, F.
    Senzel, L.
    Leung, E. L.
    Jiang, X.
    Ma, Y.
    LEUKEMIA, 2017, 31 (10) : 2151 - 2160
  • [46] A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis
    Olsen, NJ
    Brooks, RH
    Cush, JJ
    Lipsky, PE
    StClair, EW
    Matteson, EL
    Gold, KN
    Cannon, GW
    Jackson, CG
    McCune, WJ
    Fox, DA
    Teal, G
    Gruber, J
    Espinoza, L
    Caldwell, J
    Weisman, M
    Lee, S
    Abramson, S
    Calabrese, L
    Medsger, T
    Nelson, B
    Lorenz, T
    Strand, V
    ARTHRITIS AND RHEUMATISM, 1996, 39 (07): : 1102 - 1108
  • [47] Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
    K H Chen
    M Wada
    K G Pinz
    H Liu
    K-W Lin
    A Jares
    A E Firor
    X Shuai
    H Salman
    M Golightly
    F Lan
    L Senzel
    E L Leung
    X Jiang
    Y Ma
    Leukemia, 2017, 31 : 2151 - 2160
  • [48] Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells
    Jia Feng
    Haichan Xu
    Andrew Cinquina
    Zehua Wu
    Qi Chen
    Ping Zhang
    Xingen Wang
    Huiming Shan
    Lei Xu
    Qian Zhang
    Lihua Sun
    Wenli Zhang
    Kevin G. Pinz
    Masayuki Wada
    Xun Jiang
    William M Hanes
    Yupo Ma
    Hongyu Zhang
    Stem Cell Reviews and Reports, 2021, 17 : 652 - 661
  • [49] Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies
    Wada, Masayuki
    Zhang, Hongyu
    Fang, Liu
    Feng, Jia
    Tse, Charlotte Olivia
    Zhang, Wenli
    Chen, Qi
    Sha, Sha
    Cao, Yuanzhen
    Chen, Kevin H.
    Pinz, Kevin G.
    Chen, Xi
    Fan, Xing-Xing
    Jiang, Xun
    Ma, Yupo
    STEM CELL REVIEWS AND REPORTS, 2020, 16 (02) : 369 - 384
  • [50] Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells
    Feng, Jia
    Xu, Haichan
    Cinquina, Andrew
    Wu, Zehua
    Chen, Qi
    Zhang, Ping
    Wang, Xingen
    Shan, Huiming
    Xu, Lei
    Zhang, Qian
    Sun, Lihua
    Zhang, Wenli
    Pinz, Kevin G.
    Wada, Masayuki
    Jiang, Xun
    Hanes, William M.
    Ma, Yupo
    Zhang, Hongyu
    STEM CELL REVIEWS AND REPORTS, 2021, 17 (02) : 652 - 661
12345